For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| License and other revenue | 0 | 0 | 0 | 0 |
| Research and development | 59,891,000 | 54,477,000 | 41,563,000 | 42,741,000 |
| General and administrative | 19,882,000 | 13,995,000 | 12,227,000 | 11,912,000 |
| Loss from operations | -79,773,000 | -68,472,000 | -53,790,000 | -54,653,000 |
| Interest and investment income | 5,138,000 | 4,492,000 | 3,765,000 | 4,380,000 |
| Interest expense | 2,731,000 | 2,808,000 | 2,890,000 | 2,884,000 |
| Loss on extinguishment of debt | - | 0 | - | - |
| Other non-operating income (expense), net | -1,025,000 | 103,000 | -1,810,000 | 3,592,000 |
| Loss before income taxes | -78,391,000 | -66,685,000 | -54,725,000 | -49,565,000 |
| Income tax expense | 850,000 | -522,000 | 166,000 | 778,000 |
| Net loss | -79,241,000 | -66,163,000 | -54,891,000 | -50,343,000 |
| Foreign currency translation adjustment | -580,000 | 190,000 | 691,000 | -479,000 |
| Unrealized (loss) gain on available for sale securities during period, net of tax of 0.2 million in 2026 and 0 in 2025 | -483,000 | 60,750* | - | - |
| Unrealized (loss) gain on available for sale marketable securities, net of reclassification adjustment and tax | - | - | 318,000 | -5,000 |
| Reclassification adjustment for realized net (loss) gain on available for sale marketable securities included in net loss, net of tax of 0.1 million in 2026 and 0.8 million in 2025 | 243,000 | 136,750* | - | - |
| Other comprehensive (gain) income | -1,306,000 | 114,000 | 1,009,000 | -484,000 |
| Total comprehensive loss | -80,547,000 | -66,049,000 | -53,882,000 | -50,827,000 |
| Basic EPS | -0.52 | -0.465 | -0.41 | -0.38 |
| Diluted EPS | -0.52 | -0.465 | -0.41 | -0.38 |
| Basic Average Shares | 153,549,733 | 141,987,994 | 134,163,492 | 133,677,405 |
| Diluted Average Shares | 153,549,733 | 141,987,994 | 134,163,492 | 133,677,405 |
Centessa Pharmaceuticals plc (CNTA)
Centessa Pharmaceuticals plc (CNTA)